Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences

American Journal of Managed Care

Volumn 8, Issue 13 SUPPL., 2002, Pages

  Dupclay Jr , Leon ^a   Doyle, Joseph ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ABSENTEEISM; ADRENAL CORTEX INSUFFICIENCY; ALLERGIC RHINITIS; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DISEASE CONTROL; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG SAFETY; DRUG USE; EPISTAXIS; GROWTH RETARDATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LONG TERM CARE; MANAGED CARE; NOSE IRRITATION; NOSE SEPTUM PERFORATION; ODOR; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TASTE AVERSION;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; COST-BENEFIT ANALYSIS; HEALTH SERVICES RESEARCH; HUMANS; HYPERSENSITIVITY; PATIENT SATISFACTION; PRACTICE GUIDELINES; RHINITIS; UNITED STATES;

EID: 0036740440     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Sullivan SD, Weiss KB. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol. 2001;107:203-210.
2. Storms W, Meltzer EO, Nathan RA, Selner JC. The economic impact of allergic rhinitis. J Allergy Clin Immunol. 1997;99(6):S820-S824.
3. Lemanske RF. A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol. 1998;101(2):S392-S396.
4. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99:22-27.
5. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol. 1999;104:S144-S149.
6. Wihl JA, Andersson KE, Johansson SA. Systemic effects of two nasally administered glucocorticosteroids. Allergy. 1997;52(6):620-626.
7. Bachert C, El-Akkad T. Patient preference and sensory comparison of three nasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. In press.
8. American Academy of Allergy, Asthma and Immunology. Allergic Disorders: Promoting Best Practices - The Allergy Report. 2000. Available at: http://TheAllergyReport.com/main.html. Accessed March 30, 2001.
9. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999;103:401-407.
10. Stephenson J. No cures, but the remedies are improving. Business Health. 2000;4:19-25.
11. Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Managed Care. 2000;6:373-378.
12. Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Managed Care. 2000;6(suppl):S3-S20.
13. Meltzer, EO, Grant JA. Impact of cetirizine on the burden of allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83:455-463.
14. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2000;85:338-348.
15. American Academy of Allergy, Asthma, and Immunology. Fast Facts: Statistics on Asthma & Allergic Diseases, 1999. Updated October 1999. Available at: http://www.aaaai.org/public/fastfacts/statistics.stm. Accessed May 15, 2001.
16. Hewitt Associates LLC. Allergy costs may cause watery eyes for employers. Managing Health and Business Productivity. Available at: http://www.was.hewitt.com/hewitt/business/healthmgt/subhealth/hlbus_allergies.ht m. Accessed June 3, 2002.
17. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc. 1999;20:209-213.
18. Spector SL. Overview of the comorbid associations of allergic rhinitis. J Allergy Clin Immunol. 1997;99:S773-S780.
19. Fireman P. Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Allergy Asthma Proc. 1997;18:63-67.
20. Fireman P. Rhinitis and asthma connection: management of coexisting upper airway allergic diseases and asthma. Allergy Asthma Proc. 2000; 21:45-54.
21. Settipane RG, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up of college students. Allergy Asthma Proc. 1984;15:21-25.
22. Centers for Disease Control and Prevention. Allergic Rhinitis: Prevalence. Vital and Health Statistics Series 10, No. 200. May 17, 2002. Available at: http://www.cdc.gov/nchs/data/10_200_1.pdfm. Accessed June 3, 2002.
23. American Academy of Family Physicians. Facts About Family Practice - 1999. Available at: http://www.aafp.org/facts/ Tables 17, 18, 22. Accessed August 14, 2002.
24. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy. 1997;52(suppl 36):33-40.
25. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Executive summary. Ann Allergy Asthma Immunol. 1998;81:478-518.
26. Rachelefsky GS. Pharmacologic management of allergic rhinitis. J Allergy Clin Immunol. 1998;101(2):S367-369.
27. Adamopoulos G, Manolopoulos L, Giotakis I. A comparison of the efficacy and patient acceptability of budesonide and beclomethasone dipropionate aqueous nasal sprays in patients with perennial rhinitis. Clin Otolaryngol. 1995;20:340-344.
28. Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate and aqueous nasal spray for once daily treatment of perennial rhinitis. J Allergy Clin Immunol. 1998;102:902-908.
29. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol. 1997;79:370-378.
30. Skoner DP, Angelini BJ, Gentile DA, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. In press
31. Blaiss M. How to determine the cost-effectiveness of available allergic rhinitis treatments. Drug Benefit Trends. 1998;10:32-36.
32. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol. 1998;101:470-474.
33. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol. 1998;101:157-162.
34. Skoner D, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:E23.
35. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105:E22.
36. Liao E, Griffis D, Huse DM. Cost of treating allergic rhinitis and sinusitis with intranasal corticosteroids in a managed care population. JMCM. 2002;6:6-12.
37. Gross G, Jacobs RL, Woodworth TH, Georges GC, Lim JC. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:56-62.
38. Gerson I, Green L, Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sensory Stud. 1999;14:491-496.